717 related articles for article (PubMed ID: 18473749)
1. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
2. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
Zhou SF; Xue CC; Yu XQ; Li C; Wang G
Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
5. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
Zhou SF
Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
[TBL] [Abstract][Full Text] [Related]
6. Drugs as CYP3A probes, inducers, and inhibitors.
Liu YT; Hao HP; Liu CX; Wang GJ; Xie HG
Drug Metab Rev; 2007; 39(4):699-721. PubMed ID: 18058330
[TBL] [Abstract][Full Text] [Related]
7. MDR- and CYP3A4-mediated drug-herbal interactions.
Pal D; Mitra AK
Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
[TBL] [Abstract][Full Text] [Related]
8. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
10. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
11. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Dresser GK; Spence JD; Bailey DG
Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
14. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.
Luo G; Cunningham M; Kim S; Burn T; Lin J; Sinz M; Hamilton G; Rizzo C; Jolley S; Gilbert D; Downey A; Mudra D; Graham R; Carroll K; Xie J; Madan A; Parkinson A; Christ D; Selling B; LeCluyse E; Gan LS
Drug Metab Dispos; 2002 Jul; 30(7):795-804. PubMed ID: 12065438
[TBL] [Abstract][Full Text] [Related]
15. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
16. Induction of cytochrome P450 3A by Shexiang Baoxin Pill and its main components.
Jiang B; Cai F; Gao S; Meng L; Liang F; Dai X; Xu W; Chen W
Chem Biol Interact; 2012 Jan; 195(2):105-13. PubMed ID: 22178124
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
[TBL] [Abstract][Full Text] [Related]
18. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
19. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
[TBL] [Abstract][Full Text] [Related]
20. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]